

# Gastroenterology

www.gastrojournal.org

Vol. 153, No. 1

July 2017

TABLE OF CONTENTS

## Contents

### ON THE COVER



See Kaminski et al on page 98. Based on an original design by Natalia Kurowska, submitted by the authors.

### COVERING THE COVER

1 A. T. Chan and C. S. Williams

### MEETING SUMMARIES

e1 A Selection of the Best AGA Abstracts of DDW 2017  
M. Camilleri

e6 A Summary of the 2016 James W. Freston Conference of the American Gastroenterological Association: Intestinal Metaplasia in the Esophagus and Stomach: Origins, Differences, Similarities and Significance  
S. J. Spechler, J. L. Merchant, T. C. Wang, P. Chandrasoma, J. G. Fox, R. M. Genta, J. R. Goldenring, Y. Hayakawa, E. J. Kuipers, P. K. Lund, F. McKeon, J. C. Mills, R. D. Odze, R. M. Peek Jr, T. Pham, J. Que, A. K. Rustgi, N. J. Shaheen, R. A. Shivdasani, R. F. Souza, P. Storz, A. Todisco, D. H. Wang, and N. A. Wright

### MENTORING, EDUCATION, AND TRAINING CORNER

4 How to Gain Expertise in Translational Research During Training  
A. Bansal

### EDITORIALS

8 Defeating Cancer by Boosting the Adenoma Detection Rate: The Circle of Life  
C. Hassan and A. Repici

See Kaminski MF et al on page 98.

10 Making Cancer Quiescent: SPDEF De-Cycles Beta-Catenin  
B. Fingleton

See Lo Y-H et al on page 205.

Video Related article in CGH

CME quiz Editorial accompanies this article Additional online content available Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi monthly in January and May) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to GASTROENTEROLOGY, Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. 2017 US subscription rates: Individual, \$684.00; student and resident, \$261.00. Outside of the U.S. and possessions: Individual, \$968.00; student and resident, \$562.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

12 **Sno(RNA)wing and Pancreatic Cancer Metastasis***S. Ramakrishnan*

See Cui L et al on page 292.

**GASTROENTEROLOGY IN MOTION**15 **Displaced Endoscopic Ultrasound-Guided Gastroenterostomy Stent Rescued With Natural Orifice Transluminal Endoscopic Surgery***Y.-I. Chen, Y. Haito-Chavez, R. P. Bueno, M. Bukhari, O. B. Gutierrez, O. Sanaei, and M. A. Khashab***CLINICAL CHALLENGES AND IMAGES IN GI**17 **Unusual Cause of Hematochezia***N. Horvat, S. Monti, and L. Mannelli*19 **Febrile Attacks With a Refractory Colonic Lesion***T. Torisu, S. Kawatoko, and M. Esaki*21 **Crohn's and a Cough: Connecting the Dots***K. Visrodia, B. A. Dayyeh, and S. Kane*23 **"Errare Humanum Est, Perseverare Autem Diabolicum"***E. Rondonotti, G. Cengia, and F. Bonfante***ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GI**For a full list, please see the table of contents online at [www.gastrojournal.org](http://www.gastrojournal.org).**PRACTICAL TEACHING CASE**25 **Altered Bowel Habits and Pelvic Fullness in a 75-Year-Old Woman***B. Anderson and S. Sweetser***REVIEWS AND PERSPECTIVES****Brief Review**27 **Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma***J. M. Abraham and S. J. Meltzer***Reviews in Basic and Clinical Gastroenterology and Hepatology**35 **Complications of Proton Pump Inhibitor Therapy***M. F. Vaezi, Y.-X. Yang, and C. W. Howden***ORIGINAL RESEARCH****Brief Reports**49 **Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis***D. Saadoun, S. Pol, Y. Ferfar, L. Alric, C. Hezode, S. N. Si Ahmed, L. de Saint Martin, C. Comarmond, A. S. Bouyer, L. Musset, T. Poynard, M. Resche Rigon, and P. Cacoub*

Sofosbuvir plus Daclatasvir is highly and quickly effective in HCV-Cryoglobulinemia vasculitis patients. Sofosbuvir plus daclatasvir has a very good tolerance profile and reduces need for associated immunosuppressants.

53 **Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis***P. Nasr, M. F. Forsgren, S. Ignatova, N. Dahlström, G. Cedersund, O. D. Leinhard, B. Norén, M. Ekstedt, P. Lundberg, and S. Kechagias*

More patients with fatty liver can be reliably diagnosed with magnetic resonance if proton density fat fraction value of 3.0% is used as cut-off.

- 56** **Persistence of Nonceliac Wheat Sensitivity, Based on Long-term Follow-up**  
*A. Carroccio, A. D'Alcamo, G. Iacono, M. Soresi, R. Iacobucci, A. Arini, G. Geraci, F. Fayer, F. Cavataio, F. La Blasca, A. M. Florena, and P. Mansueto*

This study demonstrated that about 75% of nonceliac wheat sensitivity (NCWS) patients were still suffering from NCWS after a median follow-up time of 99 months. Thus, NCWS can be a persistent condition.

- 59** **Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease**  
*A. B. Dietz, E. J. Dozois, J. G. Fletcher, G. W. Butler, D. Radel, A. L. Lightner, M. Dave, J. Fritton, A. Nair, E. T. Camilleri, A. Dudakovic, A. J. van Wijnen, and W. A. Faubion*

A new combination product of matrix loaded with autologous Mesenchymal Stem Cells was safe and highly effective in this Phase I trial of patients with refractory perianal fistulizing Crohn's disease.

## Full Reports

### Clinical—Alimentary Tract

- 63** **Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition**  
*E. A. Ebbing, A. Steins, E. Fessler, P. Stathi, W. J. Lesterhuis, K. K. Krishnadath, L. Vermeulen, J. P. Medema, M. F. Bijlsma, and H. W. M. van Laarhoven*

Esophageal cancer cells become resistant to targeted therapies against growth factor signaling by undergoing epithelial to mesenchymal transition. Blocking both growth factor signaling and the mesenchymal transition is effective against esophageal cancer growth.

- 77** **Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study**  
*B. E. Sands, J. Chen, B. G. Feagan, M. Penney, W. A. Rees, S. Danese, P. D. R. Higgins, P. Newbold, R. Faggioni, K. Patra, J. Li, P. Klekotka, C. Morehouse, E. Pulkstenis, J. Drappa, R. van der Merwe, and R. A. Gasser Jr*

MEDI2070, an antibody against IL23, is an effective and safe agent in the short-term treatment of Crohn's disease among patients who had prior treatment with tumor necrosis factor inhibitors.

- 87** **Supplementation of Diet With Galacto-oligosaccharides Increases Bifidobacteria, but Not Insulin Sensitivity, in Obese Prediabetic Individuals**  
*E. E. Canfora, C. M. van der Beek, G. D. A. Hermes, G. H. Goossens, J. W. E. Jocken, J. J. Holst, H. M. van Eijk, K. Venema, H. Smidt, E. G. Zoetendal, C. H. C. Dejong, K. Lenaerts, and E. E. Blaak*

Supplementation of diet with the prebiotic galacto-oligosaccharides consistently increased the abundance of beneficial bifidobacteria, but no restoration of impaired glucose and insulin metabolism was observed in obese, prediabetic people.

- 98** **Increased Rate of Adenoma Detection Associates With Reduced Risk of Colorectal Cancer and Death**

*M. F. Kaminski, P. Wieszczy, M. Rupinski, U. Wojciechowska, J. Didkowska, E. Kraszewska, J. Kobiela, R. Franczyk, M. Rupinska, B. Kocot, A. Chaber-Ciopinska, J. Pachlewski, M. Polkowski, and J. Regula*

**See editorial on page 8.**

Individuals examined by endoscopists who reached or maintained their highest adenoma detection rate quintile (>24.6%) had significantly lower risk of interval colorectal cancer and death.

**106 Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives**

C. Egoavil, M. Juárez, C. Guarinos, M. Rodríguez-Soler, E. Hernández-Illán, C. Alenda, A. Payá, A. Castillejo, A. Serradesanferm, L. Bujanda, F. Fernández-Bañares, J. Cubiella, L. de-Castro, A. Guerra, E. Aguirre, A. Herreros-de-Tejada, X. Bessa, M. Herráiz, J.-C. Marín-Gabriel, J. Balmaña, V. Piñol, F. Rodríguez Moranta, D. Nicolás-Pérez, M. Cuatrecasas, F. Balaguer, A. Castells, J.-L. Soto, P. Zapater, and R. Jover

Patients with multiple serrated polyps who do not meet the criteria for serrated polyposis, and their first-degree relatives, show a similar high risk of colorectal cancer as that found in patients diagnosed with serrated polyposis.

**Clinical—Liver****113 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials**

I. M. Jacobson, E. Lawitz, E. J. Gane, B. E. Willems, P. J. Ruane, R. G. Nahass, S. M. Borgia, S. D. Shafran, K. A. Workowski, B. Pearlman, R. H. Hyland, L. M. Stamm, E. Svarovskaia, H. Dvory-Sobol, Y. Zhu, G. M. Subramanian, D. M. Brainard, J. G. McHatchison, N. Bräu, T. Berg, K. Agarwal, B. R. Bhandari, M. Davis, J. J. Feld, G. J. Dore, C. A. M. Stedman, A. J. Thompson, T. Asselah, S. K. Roberts, and G. R. Foster

In patients with HCV, 8 weeks of sofosbuvir-velpatasvir-voxilaprevir was not quite as effective as 12 weeks of sofosbuvir-velpatasvir overall due to lower cure rates in those with HCV genotype 1a.

**Basic and Translational—Alimentary Tract****123 Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease**

M. T. Chiriac, B. Buchen, A. Wandersee, G. Hundorfean, C. Günther, Y. Bourjau, S. E. Doyle, B. Frey, A. B. Ekici, C. Büttner, B. Weigmann, R. Atreya, S. Wirtz, C. Becker, J. Siebler, and M. F. Neurath

This study found that the cytokine IL28/IFN lambda promotes mucosal healing in the gut; targeting IL28 signaling might be a new therapeutic target in inflammatory bowel disease.

**139 Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function**

F. P.-L. Lai, S.-T. Lau, J. K.-L. Wong, H. Gui, R. X. Wang, T. Zhou, W. H. Lai, H.-F. Tse, P. K.-H. Tam, M.-M. Garcia-Barcelo, and E. S.-W. Ngan

Researchers established an experimental strategy combining patient-specific iPSCs, the CRISPR/Cas9 system and whole-exome sequencing data, and identified a novel mutation in *VCL* functionally contributing to short segment- Hirschsprung disease.

**154 Activation of Wnt Signaling Increases Numbers of Enteric Neurons Derived From Neonatal Mouse and Human Progenitor Cells**

Y. Zhang, K. Seid, F. Obermayr, L. Just, and P. H. Neckel

Canonical Wnt signaling enhances proliferation and neurogenesis in murine and human neural progenitor cells from the postnatal ENS.

**166 Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma**

X. Liu, M. Zhang, S. Ying, C. Zhang, R. Lin, J. Zheng, G. Zhang, D. Tian, Y. Guo, C. Du, Y. Chen, S. Chen, X. Su, J. Ji, W. Deng, X. Li, S. Qiu, R. Yan, Z. Xu, Y. Wang, Y. Guo, J. Cui, S. Zhuang, H. Yu, Q. Zheng, M. Marom, S. Sheng, G. Zhang, S. Hu, R. Li, and M. Su

Intraepithelial neoplasia and esophageal squamous cell carcinoma were found to have similar genetic variant spectrum, and DNA damage was an important mutation pattern of the carcinogenic process.

**178** **EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients**

*S. Srivatsa, M. C. Paul, C. Cardone, M. Holcmann, N. Amberg, P. Pathria, M. A. Diamanti, M. Linder, G. Timelthaler, H. P. Dienes, L. Kenner, F. Wrba, G. W. Prager, S. Rose-John, R. Eferl, G. Liguori, G. Botti, E. Martinelli, F. R. Greten, F. Ciardiello, and M. Sibilla*

EGFR expression and activation in myeloid cells promotes colorectal cancer in mice, and correlates with bad prognosis in metastatic colorectal cancer patients.

**191** **Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells**

*T. Ishimoto, K. Miyake, T. Nandi, M. Yashiro, N. Onishi, K. K. Huang, S. J. Lin, R. Kalpana, S. T. Tay, Y. Suzuki, B. C. Cho, D. Kuroda, K. Arima, D. Izumi, M. Iwatsuki, Y. Baba, E. Oki, M. Watanabe, H. Saya, K. Hirakawa, H. Baba, and P. Tan*

RHBDF2 in CAFs is up-regulated by pro-inflammatory cytokines and enhances their motility through regulating non-canonical TGF $\beta$ 1 signaling, thus inducing DGC cell invasion in extracellular matrix.

**205** **SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of  $\beta$ -catenin**

*Y.-H. Lo, T. K. Noah, M.-S. Chen, W. Zou, E. Borrás, E. Vilar, and N. F. Shroyer*

**See editorial on page 10.**

$\beta$ -catenin activity determines the proliferation or quiescence of CRC cells based on the absence or presence of SPDEF.

**219** **Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease**

*R. Gonsky, P. Fleshner, R. L. Deem, E. Biener-Ramanujan, D. Li, A. A. Potdar, J. Bilsborough, S. Yang, D. P. B. McGovern, and S. R. Targan*

RNASET2 disease-risk DNA variants are associated in Crohn's disease with clinical severity and with gene expression, biochemical pathways and epigenetic DNA modification.

**Basic and Translational—Liver****233** **Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis**

*A. King, D. D. Houlihan, D. Kavanagh, D. Haldar, N. Luu, A. Owen, S. Suresh, N. N. Than, G. Reynolds, J. Penny, H. Sumption, P. Ramachandran, N. C. Henderson, N. Kalia, J. Frampton, D. H. Adams, and P. N. Newsome*

Repeated administration of purified bone marrow stem cells reduces liver scarring in chronic liver disease. Increasing retention of bone marrow stem cells in the liver, using drugs, increases their ability to reduce liver scarring.

**249** **Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma**

*W. Zhang, H. He, M. Zang, Q. Wu, H. Zhao, L.-l. Lu, P. Ma, H. Zheng, N. Wang, Y. Zhang, S. He, X. Chen, Z. Wu, X. Wang, J. Cai, Z. Liu, Z. Sun, Y.-X. Zeng, C. Qu, and Y. Jiao*

This study identifies the genetic features of aflatoxin-associated hepatocellular carcinoma (AF-HCCs), and indicates that up to 10% of HCCs in some general population might be associated with aflatoxin exposure.

**263** **Increased Expression of Cytotoxic T-Lymphocyte-Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure**

*W. Khamri, R. D. Abeles, T. Z. Hou, A. E. Anderson, A. El-Masry, E. Triantafyllou, C. Bernsmeier, F. S. Larsen, A. Singanayagam, N. Kudo, L. A. Possamai, F. Lebosse, G. Auzinger, W. Bernal, C. Willars, C. J. Weston, G. Lombardi, J. Wendon, M. Thursz, and C. G. Antoniadis*

This study found key involvement of CTLA4, a critical negative immune regulator, in the impairment of peripheral adaptive responses in patients with acute liver failure.



**Basic and Translational—Pancreas**

- 277** **Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice**  
*S.-H. Jiang, J. Li, F.-Y. Dong, J.-Y. Yang, D.-J. Liu, X.-M. Yang, Y.-H. Wang, M.-W. Yang, X.-L. Fu, X.-X. Zhang, Q. Li, X.-F. Pang, Y.-M. Huo, J. Li, J.-F. Zhang, H.-Y. Lee, S.-J. Lee, W.-X. Qin, J.-R. Gu, Y.-W. Sun, and Z.-G. Zhang*

Locally dysregulated serotonin system enhances Warburg effect to support pancreatic cancer growth under metabolic stress.

- 292** **Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice**

*L. Cui, K. Nakano, S. Obchoei, K. Setoguchi, M. Matsumoto, T. Yamamoto, S. Obika, K. Shimada, and N. Hiraoka*

See editorial on page 12.

SNORA23, a H/ACA box-type snoRNA, is overexpressed and correlated with poor prognosis in PDAC patients, and its knockdown inhibits metastasis via inhibition of SYNE2-mediated anchor-independency and invasion in PDAC xenograft tumors.

**CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES**

- e27 Exam 1: Altered Bowel Habits and Pelvic Fullness in a 75-Year-Old Woman**
- e29 Exam 2: Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives**

**CONSENSUS GUIDELINE**

- 307 Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer**  
*D. K. Rex, C. R. Boland, J. A. Dominitz, F. M. Giardiello, D. A. Johnson, T. Kaltenbach, T. R. Levin, D. Lieberman, and D. J. Robertson*

**SELECTED SUMMARIES**

- 324 Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease**  
*D. J. Gracie and A. C. Ford*
- 325 Nutritional Care of the Patient with Gastrointestinal Disease**  
*A. Van Gossum*

**CORRESPONDENCE**

- 327 When to Search for Occult Infection After Eradication of Hepatitis C?**  
*L. De Marco and R. Pellicano*
- 327 Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?**  
*M. Enomoto, Y. Murakami, and N. Kawada*
- 328 Reply**  
*J. Kahn and T. Saito, On Behalf of the Co-investigators*
- 329 Endoscopy in Pregnant Women With Liver Cirrhosis**  
*M. D. Cannon and M. A. Heneghan*
- 330 Endoscopy for Inflammatory Bowel Disease During Pregnancy: Only When There Is a Strong Indication**  
*S. L. Kanis and C. J. van der Woude*
- 331 Reply**  
*J. F. Ludvigsson, J. Höijer, and O. Stephansson*
- 332 The Need for Appropriate Comparisons: A Response to Ravi et al**  
*K. R. Reddy, A. Osinusi, and A. J. Thompson*